CB2 cannabinoid receptor compounds boosted the effectiveness of common antidepressants in mice
In mice, both activation and blockade of CB2 receptors enhanced antidepressant effects of imipramine, escitalopram, and reboxetine without affecting brain drug levels, pointing to a pharmacodynamic interaction.
Quick Facts
What This Study Found
Sub-effective doses of JWH133 (CB2 agonist, 0.25 mg/kg) and AM630 (CB2 inverse agonist, 0.25 mg/kg) each significantly enhanced the antidepressant effects of imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) in both forced swim and tail suspension tests. Brain levels of antidepressants were unchanged, and locomotor activity was unaffected.
Key Numbers
JWH133 0.25 mg/kg + each antidepressant: significant immobility reduction in FST and TST; AM630 0.25 mg/kg + each: same effect; no brain level changes; no locomotor effects.
How They Did This
Mouse forced swim test (FST) and tail suspension test (TST) assessing combinations of CB2 receptor ligands with conventional monoaminergic antidepressants (imipramine, escitalopram, reboxetine). HPLC measured brain drug concentrations; locomotor activity monitored to rule out non-specific motor effects.
Why This Research Matters
These findings suggest CB2 receptors modulate mood independently of CB1, the more studied cannabinoid receptor. The enhancement of three different antidepressant classes (tricyclic, SSRI, NRI) suggests a broad-spectrum augmentation effect.
The Bigger Picture
CB2 receptors were long thought to be peripheral (immune system). Their role in antidepressant augmentation adds to growing evidence that CB2 plays a central role in mood regulation, opening new targets for antidepressant drug development.
What This Study Doesn't Tell Us
Animal model only; mouse behavioral tests have debated translational validity; acute dosing (no chronic studies); both agonist and antagonist showing same effect is mechanistically puzzling; only tested at single sub-effective doses.
Questions This Raises
- ?How can both CB2 activation and blockade enhance antidepressant effects?
- ?Are CB2 receptors a viable drug target for depression in humans?
Trust & Context
- Key Stat:
- CB2 agonist AND antagonist both enhanced 3 classes of antidepressants
- Evidence Grade:
- Preliminary: animal behavioral study; mechanistically intriguing but far from clinical application.
- Study Age:
- Published 2020.
- Original Title:
- Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice.
- Published In:
- Behavioural brain research, 378, 112297 (2020)
- Authors:
- Poleszak, Ewa(2), Wośko, Sylwia(2), Sławińska, Karolina(2), Wyska, Elżbieta, Szopa, Aleksandra, Sobczyński, Jan, Wróbel, Andrzej, Doboszewska, Urszula, Wlaź, Piotr, Wlaź, Aleksandra, Szponar, Jarosław, Skałecki, Piotr, Serefko, Anna
- Database ID:
- RTHC-02786
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is the CB2 receptor?
One of two main cannabinoid receptors. CB2 was originally thought to function mainly in the immune system, but growing evidence shows it also plays a role in the brain, particularly in mood regulation.
Could CB2 drugs become antidepressant boosters?
Possibly. This study found CB2 compounds enhanced three different classes of antidepressants in mice. However, the finding that both activating and blocking CB2 had the same effect is puzzling and needs mechanistic clarification before clinical development.
Read More on RethinkTHC
- LGBTQ-cannabis-use-recovery-support
- cannabis-induced-psychosis
- online-therapy-cannabis-anxiety-review
- quitting-weed-adhd
- quitting-weed-depression
- quitting-weed-ptsd
- self-medicating-with-weed
- weed-OCD-intrusive-thoughts
- weed-and-ptsd
- weed-childhood-trauma-ACE
- weed-suicidal-thoughts-withdrawal
- thc-and-ssris-cannabis-antidepressants
Cite This Study
https://rethinkthc.com/research/RTHC-02786APA
Poleszak, Ewa; Wośko, Sylwia; Sławińska, Karolina; Wyska, Elżbieta; Szopa, Aleksandra; Sobczyński, Jan; Wróbel, Andrzej; Doboszewska, Urszula; Wlaź, Piotr; Wlaź, Aleksandra; Szponar, Jarosław; Skałecki, Piotr; Serefko, Anna. (2020). Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice.. Behavioural brain research, 378, 112297. https://doi.org/10.1016/j.bbr.2019.112297
MLA
Poleszak, Ewa, et al. "Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice.." Behavioural brain research, 2020. https://doi.org/10.1016/j.bbr.2019.112297
RethinkTHC
RethinkTHC Research Database. "Ligands of the CB2 cannabinoid receptors augment activity of..." RTHC-02786. Retrieved from https://rethinkthc.com/research/poleszak-2020-ligands-of-the-cb2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.